Possibilities of PRECISE-DAPT Score for Risk Prediction of Ischemic and Hemorrhagic Events in ST-Elevated Myocardial Infarction (According to the Data of the Registry Study in Kemerovo)

Aim. We aimed to study in real clinical practice the clinical and anamnestic characteristics, the peculiarities of double antiplatelet therapy (DAPT) prescription as well the incidence of ischemic and hemorrhagic events in patients with ST-elevated myocardial infarction (MI) during a year of follow-up, taking into account the baseline PRECISE-DAPT scores.

Material and methods. The study included 680 patients with MI from the database of Kemerovo observational registry for acute coronary syndrome (ACS). All the patients retrospectively underwent an individual calculation using the PRECISE-DAPT score. Then, depending on the number of the points, all the patients were divided into the low (less than 25 points) and high (25 or more points) risks groups. Differences in clinical and anamnestic parameters, the peculiarities of DAPT prescription, as well as the incidence of ischemic and hemorrhagic outcomes during a year of follow-up after MI were estimated in the groups.

Results. The Russian patients with ST-elevated MI and the high PRECISE-DAPT hemorrhagic risk score had a history of renal pathology (р=0.010), multivessel coronary artery disease and polyvascular disease (р=0.002), prior angina pectoris (р=0.001), as well as the course of the index event with the manifestations of acute coronary failure (р=0.001) more often than the patients from the low-risk group. The patients of the high-risk group less often underwent coronary angiography with stenting (р=0.001), as well as coronary artery bypass grafting (р=0.010) at hospitalization and had a higher in-hospital mortality rate (р=0.002). The patients at high hemorrhagic risk according to the PRECISE-DAPT score were less often prescribed with DAPT within a year after MI (р=0.001) and aspirin monotherapy was preferred more often (р=0.001). At the same time, the patients at high hemorrhagic risk on the PRECISE-DAPT score had more often major bleedings, recurrent MI and deaths (р=0.001) within a year after MI.

Conclusion. In the present study, the possibilities of risk assessment with the PRECISE-DAPT score were retrospectively tested on the sample of patients with MI from the ACS registry in Kemerovo city. Good identification of patients with the high risks of hemorrhagic events and ischemic outcomes within 12 months of the follow-up after index MI has been shown, which allows to recommend the PRECISE-DAPT score for a clinical practice in order to rationalize the approaches to DAPT prescription and to optimize the existing approaches to the comprehensive risk assessment of patients with ACS along with existing scales.

1. Boytsov S.A. Prevention of noncommunicable diseases in the country: from «what to do» to «how to do». Preventive Medicine. 2012;2:3-10 (In Russ.)

2. Barbarash O.L. European program «Stent for life initiative»: background, history, aims and goals. Complex Issues of Cardiovascular Diseases. 2013;1:10-8 (In Russ.)

3. Barbarash O.L., Kashtalap V.V. The place of pharmacoinvasive management in patients with ST-elevation acute Coronary syndrome in Russia. Kardiologiaa. 2014;54(9):79-85 (In Russ.)

4. Sedykh D.Y., Gorbunova E.V., Zykov M.V., et al. Factors associated with the risk of death and hospitalization in recurrent myocardial infarction. Creative Cardiology. 2017;11(2):98-108 (In Russ.) DOI:10.24022/1997-3187-2017-11-2-98-108.

5. Barbarash O.L., Karetnikova V.N., Kashtalap V.V. The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? Cardiosomatics 2015;6(2):12-9 (In Russ.)

6. Erlikh A.D. Dual antiplatelet therapy: needs for compliance to therapy and possibilities its increase. Atherothrombosis. 2014;2:25-33 (In Russ.)

7. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-77. doi:10.1093/eurheartj/ehx393.

8. Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213-54. DOI:10.1093/eurheartj/ehx419.

9. Cosentino N., Campodonico J., Faggiano P., et al. A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction. Int J Cardiol. 2019;278:1-6. DOI:10.1016/j.ijcard.2018.11.142.

10. Costa F., Van Klaveren D., James S., et al. Derivation and validation of predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISEDAPT) score: pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-34. DOI:10.1016/S0140-6736(17)30397-5.

11. Diagnosis and treatment of patients with acute myocardial infarction with elevations of the ST segment of the electrocardiogram. Clinical guidelines, 2016. [cited by Sep 06, 2019]. Available from: http://cr.rosminzdrav.ru/#!/recomend/135. (In Russ.)

12. Khomitskaya Y.V., Averkov O.V., Ruda M.Y. Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome patients in Russia: an observational study (EPICORRUS study). Emergency Cardiology. 2017;2:23-36 (In Russ.)

13. Erlikh A.D. Twelve months outcomes in patients with acute coronary syndrome, by the National registry RECORD-3. Russ J Cardiol. 2018;3(155):23-30 (In Russ.) DOI:10.15829/1560-40712018-3-23-30.

14. Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Y. Treatment of patients with chronic ischemic heart disease in real clinical practice according to the data from PROGNOZ IBS register (part 2). Rational Pharmacotherapy in Cardiology. 2013;9(5):494-9 (In Russ.) DOI:10.20996/1819-6446-2013-9-5-494-499.

15. Abu-Assi E., Raposeiras-Roubin S., Garcia-Acuna J.M., et al. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol. 2014;6(11):1140-8. DOI:10.4330/wjc.v6.i11.1140.

16. Sanfelix-Gimeno G., Peiro S., Ferreros I., et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. Journal of managed care pharmacy (JMCP) 2013;3(19):247-57. DOI:10.18553/jmcp.2013.19.3.247.

17. Smolina K., Wright F.L., Rayner M. et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes. 2012;5:532-40. DOI:10.1161/CIRCOUTCOMES.111.964700.

18. Barbarash O.L., Zykov M.V., Kashtalap V.V., et al. Evaluation of inflammation factors in patients with ST-segment elevation myocardial infarction and multifocal atherosclerosis. Cardiology and Cardiovascular Surgery. 2010;3(6):20-6 (In Russ.)

19. Kashtalap V.V., Barbarash O.L. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medical Council. 2017;12:82-8 (In Russ.) DOI:10.21518/2079-701X-2017-12-82-88.